- Home
- SNY vs UBER Comparison
SNY vs UBER Comparison
Compare SNY & UBER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- UBER
- Stock Information
- Founded
- SNY 1994
- UBER 2009
- Country
- SNY France
- UBER United States
- Employees
- SNY N/A
- UBER N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- UBER Business Services
- Sector
- SNY Health Care
- UBER Consumer Discretionary
- Exchange
- SNY Nasdaq
- UBER Nasdaq
- Market Cap
- SNY 123.6B
- UBER N/A
- IPO Year
- SNY N/A
- UBER 2019
- Fundamental
- Price
- SNY $52.13
- UBER $82.30
- Analyst Decision
- SNY Buy
- UBER Strong Buy
- Analyst Count
- SNY 2
- UBER 33
- Target Price
- SNY $62.50
- UBER $93.70
- AVG Volume (30 Days)
- SNY 3.1M
- UBER 20.8M
- Earning Date
- SNY 04-24-2025
- UBER 05-07-2025
- Dividend Yield
- SNY 3.09%
- UBER N/A
- EPS Growth
- SNY 39.56
- UBER 808.82
- EPS
- SNY 5.45
- UBER 5.66
- Revenue
- SNY $48,817,552,946.00
- UBER $45,380,000,000.00
- Revenue This Year
- SNY $5.35
- UBER $16.62
- Revenue Next Year
- SNY $6.69
- UBER $14.52
- P/E Ratio
- SNY $9.56
- UBER $14.54
- Revenue Growth
- SNY N/A
- UBER 17.60
- 52 Week Low
- SNY $45.80
- UBER $54.84
- 52 Week High
- SNY $60.12
- UBER $87.00
- Technical
- Relative Strength Index (RSI)
- SNY 44.93
- UBER 60.63
- Support Level
- SNY $51.67
- UBER $80.12
- Resistance Level
- SNY $55.73
- UBER $86.57
- Average True Range (ATR)
- SNY 0.90
- UBER 3.15
- MACD
- SNY 0.10
- UBER 0.70
- Stochastic Oscillator
- SNY 31.69
- UBER 72.09
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.